We are live on ! Find out more
VBIV

VBI Vaccines, Inc. New Common Stock (Canada)
VBIV

Delisted

VBIV was delisted on the 7th of August, 2024.

Back to rankings

127 hedge funds and large institutions have $69.9M invested in VBI Vaccines, Inc. New Common Stock (Canada) in 2022 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 29 increasing their positions, 50 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

488% more call options, than puts

Call options by funds: $382K | Put options by funds: $65K

2% less funds holding

Funds holding: 130 → 127 (-3)

15% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 13

16% less capital invested

Capital invested by funds: $83.3M → $69.9M (-$13.4M)

42% less repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 50

Holders
127
Holders Change
-3
Holders Change %
-2.31%
% of All Funds
2.18%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
29
Reduced
50
Closed
13
Calls
$382K
Puts
$65K
Net Calls
+$317K
Net Calls Change
+$9K

Top Buyers

Rank Fund Capital Flow
1
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors
Iowa
+$808K
2
State Street
State Street
Massachusetts
+$569K
3
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors
North Carolina
+$541K
4
Invesco
Invesco
Georgia
+$174K
5
WAAG
Wealth Alliance Advisory Group
Kansas
+$163K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$1.57M
2
Goldman Sachs
Goldman Sachs
New York
-$816K
3
Millennium Management
Millennium Management
New York
-$594K
4
E
Ergoteles
New York
-$447K
5
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
-$403K

VBIV Hedge Fund Activity: Q3 2022 in Review

127 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) for Q3 2022, worth a combined $69.9M — down 16% from $83.3M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of VBIV and 11 opened new positions — a net loss of 2 holders — while 50 trimmed existing stakes and 29 added.

The largest buyer was Cambridge Investment Research Advisors, adding an estimated $808K. The largest seller was Vanguard Group, cutting an estimated $1.57M.

  • 127 institutional investors held VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) as of Q3 2022, down from 130 in Q2 2022.
  • Funds reported $69.9M of VBI Vaccines, Inc. New Common Stock (Canada) stock for Q3 2022, down 16% quarter-over-quarter.
  • 11 funds opened new VBI Vaccines, Inc. New Common Stock (Canada) positions in Q3 2022 and 13 closed out, a net change of -2 holders.
  • The largest VBI Vaccines, Inc. New Common Stock (Canada) buyer in Q3 2022 was Cambridge Investment Research Advisors, an estimated $808K added.
  • The largest VBI Vaccines, Inc. New Common Stock (Canada) seller in Q3 2022 was Vanguard Group, an estimated $1.57M sold.

Based on aggregated 13F filings for Q3 2022.